Beijing News On December 18, Lilly's official WeChat official account announced that its Alzheimer's disease treatment Donetumab injection (trade name: Minonda®, Intravenous infusion once every four weeks has been approved by the National Medical Products Administration for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease in adults.
Alzheimer's disease is a fatal disease that can lead to gradual decline in memory and other cognitive functions, and is one of the leading causes of death. It is estimated that 32 million people worldwide suffer from Alzheimer's disease dementia and have confirmed pathological changes in amyloid protein. Meanwhile, Alzheimer's disease also imposes a heavy economic burden on families and society.
Starch like protein is a naturally occurring protein in the body that can aggregate together to form amyloid plaques. The excessive accumulation of amyloid plaques in the brain may lead to memory and thinking problems associated with Alzheimer's disease. Ji Nengda& reg; It can help the body clear excessive accumulation of amyloid plaques and slow down situations that may cause people to forget information, cook, manage finances, and decline in independent self-care abilities.